In a recent study by Cho et al., it was revealed that engineered exosomes derived from primary CD8+ T cells expressing IL-2 and anti-EGFR antibodies not only demonstrated potent antitumor effects on A549 human lung cancer cells but also exhibited an augmented capacity for cancer targetability34. This evidence concerns the gene CD8A and cancer.